Velaglucerase alfa
pharmaceutical drug
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme. It is manufactured by Shire plc.
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.
Velaglucerase alfa was approved for medical use in the United States in February 2010, and in the European Union in August 2010.
Medical uses
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.
“Velaglucerase alfa” enters the record as pharmaceutical drug. Crown Archives preserves that source wording while asking what Velaglucerase, alfa and pharmaceutical can confirm, complicate or overturn.
Why this record matters
“Velaglucerase alfa” is worth following because a concise public description often conceals a longer documentary argument. Here, Velaglucerase, alfa and pharmaceutical provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jul 16, 2024. The linked authority identifier is Q3492447. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2010.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Velaglucerase alfa”, its source revision and the description used here.
- Expand the search: follow Velaglucerase alfa primary sources, Velaglucerase alfa archive and Velaglucerase research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Velaglucerase alfa”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Velaglucerase alfa” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.